Riskpilot← Back to searchSign inGet full accessVIAD PHARMA ApS
APSActiveCVR 36433892Hejrevej 39Engineering activities and related technical consultancy · NACE 7112Est. 20141 employees
Revenue 2025
DKK 1M
-39% vs 2024
EBITDA margin
26.3%
-71% vs 2024
Equity ratio
11.4%
Financial strength
Net profit 2025
DKK 168K
-76% vs 2024
| Revenue | DKK 1M | -39% |
| EBITDA | DKK 271K | -71% |
| Net profit | DKK 168K | -76% |
| Total assets | DKK 2,1M | +11% |
| Equity | DKK 236K | -69% |
| Employees | 1 | — |
Legal name
VIAD PHARMA ApS
CVR number
36433892
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
1. november 2014
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive konsulentvirksomhed, herunder konsulentvirksomhed inden for lægemiddelbranchen og anden dermed i forbindelse stående konsulentvirksomhed.
Address
Hejrevej 39
Phone
+4540551565
Email
hm@viadpharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.627 | 1.442 | 1.538 | 1.372 | 1.410 | 1.291 | 1.048 | 1.007 | 1.258 | 1.694 | 1.031 |
| Staff expenses | -723 | -610 | -667 | -653 | -685 | -685 | -689 | -688 | -694 | -764 | -760 |
| EBITDA | 904 | 833 | 871 | 718 | 725 | 606 | 359 | 318 | 564 | 931 | 271 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 904 | 833 | 871 | 718 | 725 | 606 | 359 | 318 | 564 | 931 | 271 |
| Net financials | -4 | -0 | -1 | -8 | -11 | -18 | -37 | -76 | -80 | -42 | -54 |
| Profit before tax | 900 | 832 | 870 | 710 | 714 | 588 | 323 | 242 | 484 | 889 | 217 |
| Tax | 189 | 209 | 193 | 158 | 159 | 130 | 72 | 54 | 107 | 197 | 49 |
| Net profit | 711 | 623 | 677 | 553 | 555 | 458 | 250 | 188 | 376 | 692 | 168 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 848 | 984 | 1.119 | 1.559 | 1.026 | 1.768 | 1.988 | 2.288 | 2.914 | 1.867 | 2.069 |
| Equity | 761 | 684 | 761 | 714 | 668 | 526 | 319 | 257 | 445 | 761 | 236 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 86 | 300 | 358 | 845 | 357 | 1.242 | 1.669 | 2.032 | 2.469 | 1.106 | 1.832 |
| Total debt | 86 | 300 | 358 | 845 | 357 | 1.242 | 1.669 | 2.032 | 2.469 | 1.106 | 1.832 |
EBITDA margin
26.3%
This company
15.8%
Market median
+66% vs market
20152025
Equity ratio
11.4%
This company
38.2%
Market median
-70% vs market
20152025
Return on equity
71.1%
This company
18.4%
Market median
+286% vs market
20152025
Net profit margin
16.3%
This company
8.1%
Market median
+101% vs market
20152025
Asset turnover
0.50×
This company
1.12×
Market median
-55% vs market
20152025
Debt / equity
7.75×
This company
0.62×
Market median
-1150% vs market
20152025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-11-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HM Management | Management | 2014 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HEIDI MEIER HOLDING ApS | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HEIDI MEIER HOLDING ApS
VIAD PHARMA ApS Board members of VIAD PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Heidi Meier | Management | 0 companies |